Date: Wednesday, January 29 at 1PM-2PM ET
Description:
During this webinar, we will provide a brief introduction to the Grant Engine team and expertise, discuss the advantages of non-dilutive funding, provide strategic tips and common pitfalls, and offer guidance on collaborating with a grant writing partner.
First, we will emphasize the significant advantages of securing non-dilutive funding through grants and contracts for companies developing innovative products: high return on investment, validation from prominent agencies like NIH, and potentially faster funding cycles than equity fundraising.
Next, we highlight strategies and approaches that can improve your win rate to 2-4x higher than the national average, attributed to steps differentiated and proprietary process.
Then, strategic approaches are outlined for securing funding from agencies such as the NIH, Department of Defense, and BARDA. Their playbook for success includes defining a Target Product Profile, leveraging existing databases to understand prior awards, engaging with program officials and identifying internal champions within the funding agency, and high-quality grant writing.
Finally, we emphasize the expertise and experience of Grant Engine team across various disease areas and product types, as well as a collaborative workflow that ensures successful grant applications in partnership with us.
Speakers:
Sam Tetlow, CEO, Grant Engine
**You must be current MTEC Member in good standing in order to attend**
